Core Insights - The transaction indicates a significant insider purchase by Srinivas Akkaraju, Director of Alumis, acquiring 588,235 shares for approximately $10.0 million, reflecting a strong belief in the company's future performance [5][6]. Company Overview - Alumis is a clinical-stage biotechnology company focused on developing therapies for autoimmune and neuroinflammatory diseases, leveraging advanced TYK2 inhibitor technology to address unmet medical needs [7]. Transaction Details - The shares were purchased at $17.00 each, which is below recent market prices, suggesting a favorable entry point for the insider [2][6]. - This acquisition is one of the largest recorded for Akkaraju, increasing his cumulative indirect holdings by nearly 47% in a single transaction [4][5]. Market Performance - Alumis' stock has appreciated significantly, with a 206.29% increase over the past year and over 400% in the last three months, indicating strong market confidence [5][8]. - The company recently reported successful phase 3 trial results for envudeucitinib, showing that 65% of patients achieved a 90% or better improvement in psoriasis severity scores [9]. Competitive Landscape - Alumis' psoriasis treatment candidate appears to be more effective than Amgen's Otezla, which had 33% of patients achieving a 75% improvement in similar trials [10].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline due to FDA feedback on its gene therapy AMT-130 [1][4]. Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) [2]. - The FDA no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission [2]. Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Alvotech's stock price experienced a significant decline of 34% on November 3, 2025, following the announcement of a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05 [3]. - The FDA's CRL indicated that certain deficiencies identified during a pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA for AVT05 can be approved [3]. Group 2: Legal Action - Investors who purchased Alvotech securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4].

关注投资家，⭐，您会收到最新推送 作者 | 黄蓉 来源 | FOFWEEKLY 在全国一级市场逐步回暖、地方政府引导基金加速扩容的背景下，四川正以制度创新和资本集聚，悄然 描绘中西部创投版图。 3500亿基金赋能新质生产力 1 月 14 日，"2026 成都高新区产业・资本对接会" 在菁蓉汇举行。成都高新区财政国资局副局长周至涯 在会上透露，区域内已签约基金 174 只，总规模达 3553 亿元，其中 120 只基金已进入投资期，正在加 速投向电子信息、医药健康、人工智能等重点产业。 与大会同步发布的，还有两份关键清单 ： 为吸引GP落地四川，《措施》还提出一系列真金白银的奖励机制。包括对贡献突出的创业投资基金管 理人高级管理人员，依法依规给予给予税收、医疗、子女入学、住房保障等支持，对机构给予不超过 200万元给予奖励等举措。 在这一整套政策体系的推动下，四川创投生态被持续激活，基金数量和规模快速增长。 四川省产业投资引导基金有限公司董事长朱向东介绍，截至2025年12月底，共批准设立50支省级政府引 导基金，目标总规模992.63亿元。 四川创投多点开花 四川创投市场的崛起，并非成都一枝独秀，而是全域协同 ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are alleged to have purchased Vistagen common stock at artificially inflated prices due to these misleading statements, resulting in damages when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Vistagen Therapeutics common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. on behalf of purchasers of its common stock between April 1, 2024, and December 16, 2025, due to misleading statements regarding the company's drug fasedienol and its clinical trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are eligible for compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Vistagen common stock during the class period [2][3]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel [4]. - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly [3][7].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Market and analyst sentiment on ImmunityBio, Inc. ( IBRX ) has waxed and waned since I have been watching the company starting back in late 2023 , prior to the approvalI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: ...

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333-291993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________ HELIX ACQUISITION CORP. III (Exact name of registrant as specified in its charter) ______________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdict ...

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333-292331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrants as Specified in its Charter) ____________________________ | Delaware | 6770 | 86-1314502 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard I ...